

South Korean startup Neurophet's AI brain imaging device gets approval in Singapore

17 April 2023 | News

Completion of HSA certification for two flagship products for brain imaging diagnosis, 'Neurofit Aqua' and 'Neurofit Scale Pet'

Neurophet, a company specialising in artificial intelligence (AI) solutions for brain disease imaging, has obtained medical device certification for its neurodegeneration image analysis software, Neurophet AQUA, from the Health Sciences Authority (HSA) of Singapore.

In December last year, Neurophet obtained medical device certification for its automatic PET image analysis software, Neurophet SCALE PET, from HSA.

Neurophet Aqua is a brain image analysis software medical device that analyses brain atrophy and white matter degeneration observed in neurodegenerative diseases such as Alzheimer's disease and vascular dementia by analysing brain magnetic resonance imaging (MRI) with AI technology.

Based on the AI engine, Neurophet Aqua can segment and analyse brain images in 5 minutes, and boasts a high analysis success rate with an analysis failure rate of 0%. Brain image analysis is possible regardless of race, age, and gender, and consistent analysis results are derived from images of various MRI devices such as global MRI device manufacturers GE, Philips, and Canon.

Neurophet is speeding up its penetration into the Southeast Asian market by collaborating with a university that conducts multidisciplinary brain disease research in Singapore. In November last year, the startup had signed a joint research agreement on brain image analysis with the Dementia Research Center affiliated with Nanyang Technological University (Lee Kong Chian School of Medicine) to study dementia using Neurophet Aqua.